Trial reportAmerican journal of hematology2021
Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m
Open access · hybridAbstract readClinical Trial, Phase IClinical Trial, Phase IILetter
In one paragraph
Trial report in American journal of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 13 citations in OpenAlex.
- Cardiotoxicity induced by multiple myeloma therapies: mechanistic convergence across proteasome inhibitors, CAR-T, and bispecific antibodies.Blood cancer journal · 2026Review
- Evidence for the Monitoring of Minimal Residual Disease Dynamics to Guide Clinical Practice in Patients with Multiple Myeloma.Targeted oncology · 2026Review
- Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features.Nature communications · 2024Article
- Response-Adapted Therapy for Newly Diagnosed Multiple Myeloma.Current hematologic malignancy reports · 2023Review
- Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma.Journal of hematology & oncology · 2021Article
- Efficacy and Toxicity Profile of Carfilzomib-Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review.OncoTargets and therapy · 2021Review
- Tumor Reduction in Multiple Myeloma: New Concepts for New Therapeutics.Frontiers in oncology · 2021Article
- The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift?British journal of haematology · 2020Review
- Moving Toward Continuous Therapy in Multiple Myeloma.Clinical hematology international · 2019Review
- Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma.Leukemia · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 3 institutions in 1 country.
Neha KordeMultiple Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0002-5538-4318
Donna MasteyMultiple Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Elizabet TavitianMultiple Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Sham MailankodyMultiple Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Alexander LesokhinMultiple Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Hani HassounMultiple Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Eric L SmithMedical Oncology, Dana-Farber Cancer Institute, New York, New York, USA.
Nikoletta LendvaiMultiple Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Malin HultcrantzMultiple Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Urvi ShahMultiple Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Carlyn TanMultiple Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Sydney LuMultiple Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Benjamin DiamondMultiple Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Meghan SalcedoMultiple Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Kelly WernerMultiple Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
David J ChungDepartment of Medicine, Weill Cornell Medical College, New York, New York, USA.
Michael ScordoDepartment of Medicine, Weill Cornell Medical College, New York, New York, USA.
Gunjan L ShahDepartment of Medicine, Weill Cornell Medical College, New York, New York, USA.
Oscar LahoudDepartment of Medicine, Weill Cornell Medical College, New York, New York, USA.
Heather LandauDepartment of Medicine, Weill Cornell Medical College, New York, New York, USA.
Maria ArcilaHematopathology Services, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Caleb HoHematopathology Services, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Mikhail RoshalHematopathology Services, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Ahmet DoganHematopathology Services, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Andriy DerkachDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Sean M DevlinDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Sergio A GiraltDepartment of Medicine, Weill Cornell Medical College, New York, New York, USA.
Ola LandgrenMultiple Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Memorial Sloan Kettering Cancer Center · USCornell University · USDana-Farber Cancer Institute · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MUnderstanding and addressing sub-optimal responses to CAR T cell therapy for Multiple MyelomaK08CA241400 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SMITH, ERIC L · 2019 to 2023
$1.3MNCI NIH HHS K08 CA241400NCI NIH HHS P30 CA008748
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAlgorithmsAntineoplastic Combined Chemotherapy ProtocolsClinical Decision-MakingDexamethasoneFemaleGastrointestinal DiseasesHeart DiseasesHematologic DiseasesHumansLenalidomideMaleMiddle AgedMultiple MyelomaNeoplasm, ResidualcarfilzomibDexamethasoneLenalidomideOligopeptides
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.